The increasing use of screening technologies in malaria research has substantially expanded our knowledge on cellular factors hijacked by the Plasmodium parasite in the infected host, including those that participate in the clinically silent liver stage. This rapid gain in our understanding of the hepatic interaction partners now requires a means to validate and further disentangle parasite-host networks in physiologically relevant liver model systems. Here, we outline seminal work that contributed to our present knowledge on the intrahepatic Plasmodium host factors, followed by a discussion of surrogate models of mammalian livers or hepatocytes. We finally describe how Adeno-associated viruses could be engineered and used as hepatotropic tools to dissect Plasmodium-host interactions, and to deliberately control these networks for antimalaria vaccination or therapy.
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Keywords: 3D culture; AAV; adeno-associated virus; liver; malaria; Plasmodium Malaria is a devastating infectious disease that kills 438 000 people a year worldwide [1] , mainly children -one every 30 s. An effective vaccine is widely regarded as an essential tool for sustainable malaria control. To date, attenuated whole parasites and wildtype parasites under drug cover have been shown to induce complete sterilizing immunity [2] [3] [4] [5] [6] , but numerous practical issues make it unlikely that this vaccine type could be licensed for common use in humans. This may differ for the latest subunit of malaria vaccine candidates, which are best represented by Mosquirix/RTS,S and which have recently obtained market authorization by the European Medicines Agency [7] .
While a pivotal step in the field and a significant scientific achievement, the enthusiasm is unfortunately dampened by clinical data implying that Mosquirix only yields modest protection against malaria infection [8] [9] [10] . In fact, it was concluded that a bed net remains more effective than this vaccine.
In general, a seminal reason for the persisting lack of better vaccines is the gaps in our understanding of the interactions of the malaria parasite, Plasmodium, with its human host in vivo. This is especially the case for the first site in the infected body, namely, the liver -the bridgehead of malaria infection where Plasmodium develops further after the bite of an infected Abbreviations AAV, Adeno-associated viral; CSP, circumsporozoite protein; ER, endoplasmic reticulum; FGF, fibroblast growth factor; HBV, Hepatitis B virus; HCV, Hepatitis C virus; HGF, hepatocyte growth factor; HO-1, heme oxygenase 1; HSPGs, heparan sulfate proteogylcans; IFN, interferon; iPSCs, induced pluripotent stem cells; ISGs, interferon-stimulated genes; L-FABP, liver-fatty acid-binding protein; LSEC, liver sinusoidal endothelial cells; MAVS, mitochondrial antiviral signaling protein; MDA5, melanoma differentiation-associated gene 5; miRNA, microRNA; MPCC, micropatterned cocultivation; MSC, mesenchymal stem cells; ORFs, open reading frames; PV, parasitophorous vacuole; ss, singlestranded; TRAP, thrombospondin-related adhesion protein; UIS3, up-regulated in sporozoites 3.
Anopheles mosquito. In principle, a single infectious sporozoite reaching the liver and completing its intrahepatic development suffices to give rise to up to 10 000 merozoites capable of invading erythrocytes and causing malaria pathology [11, 12] . Before productively invading a final host hepatocyte, sporozoites transmigrate through multiple hepatocytes, whereby the parasites breach the cell plasma membrane and glide through the cytosol before exiting the cell [13] ( Fig. 1) . Eventually sporozoites initiate a transformation process in their final host cell and develop into liver trophozoites. Multiple rounds of DNA replication and nuclear divisions without subsequent mitosis (i.e., schizogony) then lead to the formation of a multinuclear syncytium, the so-called schizont. Subsequent repeated invaginations of the schizont plasma membrane result in the generation of individual first-generation merozoites. Finally, the infected host cell detaches from its surroundings, and merozoites packaged in vesicles called merosomes bud off the detached cell and are released into the blood stream, to initiate the intraerythrocytic stage [14] .
Curiously, as noted, parasite propagation within hepatocytes is not accompanied by disease symptoms; instead, malaria pathology starts with the transition of parasites from the liver into the blood where they repeatedly infect red blood cells. Hence, only interventions that target the clinically silent pre-erythrocytic stages, that is, before the parasite enters the blood, can mediate complete sterilizing protection and thereby prevent malaria disease. In turn, this creates an urgent need to fully dissect the molecular repertoire of intrahepatic Plasmodium stages and their interplay with the host cells. It is, thus, even more puzzling how poorly these factors and mechanisms have been characterized to date, as compared to the pathogenic erythrocytic Plasmodium stages and also considering that the intrahepatic stages were discovered more than 60 years ago.
In this review, we first summarize recent pivotal advances in identifying host factors that promote or restrict parasite liver-stage development, and point out remaining gaps in our knowledge of host contributions to hepatic malaria infection. Subsequently, we highlight newly emerging key technologies and strategies that should ultimately permit dissection of parasitehost interactions within hepatocytes in much greater detail. Our specific focus is on (a) novel surrogate models of whole livers that could replace animal experimentation in the future, as well as on (b) recombinant Adeno-associated viruses as a powerful, versatile, and ideally suited tool to study or perturb Plasmodium-host interactions ex or in vivo.
Wanted ex or in vivo-host factors involved in intrahepatic Plasmodium development Sporozoite infection follows a very specific path in the mammalian host, largely dictated by interactions with distinct cellular factors. It is initiated by the extravascular inoculation of infectious single-celled sporozoites into the skin by anopheline mosquito bites [15, 16] . Once deposited into the skin, they reach and invade the vasculature to be passively transported by the blood flow until they eventually arrive at the liver [17] . There, the infectious malarial sporozoites arrest at the liver endothelium due to a specific interaction between both, their major surface proteins, circumsporozoite protein (CSP) and thrombospondin-related adhesion protein (TRAP), with highly sulfated heparan sulfate proteogylcans (HSPGs) presented by stellate cells and hepatocytes [18] [19] [20] . Within the infected hepatocyte, the highly differentiating and replicative parasite resides in a membranous compartment. In addition to its own plasma membrane, this so-called parasitophorous vacuole (PV) physically separates the parasite from the host cell cytoplasm [11, 21] (see also Fig. 1 ).
To date, only few studies have investigated which host-specific factors next to HSPGs are exploited by the parasite, and thereby contribute to the establishment and maintenance of its intrahepatic development. The first host factors involved in Plasmodium sporozoite invasion were identified either as a direct protein interaction partner of a Plasmodium-specific protein, or because they were already known to be important for infection with other hepatotropic pathogens such as Hepatitis C virus (HCV). In this manner, the tetraspanin CD81, a surface molecule on hepatocytes and one of the main receptors for HCV [22, 23] , was identified as a crucial host factor for hepatocyte invasion of both, P. falciparum and P. yoelii sporozoites [23] [24] [25] . Similarly, Cha and coworkers determined a critical role of host CD68 as a putative receptor for sporozoite invasion and traversal of Kupffer cells [26] . A final relevant example is the host protein L-FABP (liver-fatty acid-binding protein) that was found to specifically interact with the PV membrane-resident protein, UIS3 (up-regulated in sporozoites 3, [27] ) within the infected hepatocyte, and which is presumably required for fatty acid uptake into the parasite [28] .
A limitation of these approaches, which focus on single factors, is that the assessment of individual proteins is labor-intensive and requires a priori knowledge of promising candidates. Therefore, a number of groups conducted high-throughput screens with the aim to evaluate the contribution of a wider variety of potential host factors to Plasmodium liver-stage development. Typically, these screens were based on siRNA knock-down of a set of genes in human hepatoma cell lines prior to infection with the rodent parasite P. berghei. In one such comprehensive approach, 727 genes belonging to the human kinome were assessed individually and stringently, resulting in the identification of five kinases that are required for P. berghei liver stages [29] . One of the hits was PKCf, a member of the PKC family. More specifically, it belongs to the atypical PKCs that are involved in various cellular processes such as cell growth and survival as well as regulation of NFΚB [30] . Further in vitro experiments revealed that PKCf is required for sporozoite invasion into hepatocytes, but not for liver-stage development. Interestingly, mice that had received a siRNA-targeting PKCf had reduced liver burdens and exhibited a delay in the onset of blood-stage parasitemia [29] .
In a similar approach, all lipoprotein-related host factors-a total of 53 genes-were screened for their contribution to Plasmodium infection, leading to the identification of the class B, type I scavenger receptor (SR-BI) as an important candidate [31] . The authors of this work could show that SR-BI is required for both, invasion and intracellular development of P. berghei and P. falciparum, respectively. A lack of SR-BI impedes liver-stage development in vitro and in vivo, albeit studies with blocking antibodies revealed that no direct interaction is needed between SR-BI and the infectious sporozoite [31] [32] [33] . It is intriguing to speculate that the cholesterol, which is provided by SR-BI and incorporated into the plasma membrane, is important for parasite invasion; perhaps it may also serve as a lipid source during growth. Notably, HCV entry depends on SR-BI as well, and cholesterol and antagonists against this receptor are currently under clinical investigation [34] [35] [36] [37] .
In the aforementioned studies, the assays were restricted to a preselected group of genes due to the limitations of RNAi-based screening platforms. Also, only loss-of-function effects on parasite development could be assessed, but not the natural response of the host cell to infection. In fact, transcriptional changes upon productive hepatocyte infection are not restricted to the Plasmodium parasite, but the host cell, too, responds with numerous alterations in gene expression. To begin to unravel these, Albuquerque and colleagues performed an unbiased assessment of the global host response to Plasmodium infection, using high-throughput microarray technology to measure genome-wide transcriptional changes in murine hepatoma cells upon infection with P. berghei [38] . Strikingly, they found 1064 host genes to be expressed differentially at one or more of the selected time points (6, 12, 18 , or 24 h post infection), and noted that transcriptional changes followed a coordinated and timed pattern. Based on their data, it seems that once infected, the host cell initially mounts a stress response to the presence of the parasite. This is followed by subsequent engagement of diverse metabolic pathways, presumably to cope with the parasite's rapid proliferation and energy needs. At all times, genes involved in cell death and apoptosis are regulated differentially in order to maintain viability of the host cell [39] [40] [41] . Furthermore, the developing intrahepatic parasite is highly metabolically active and up-regulates various pathways, such as redox, mitochondrial citric acid cycle, apicoplastic FAS II pathway, and glycolysis, among several others [42] .
Notably, some of the hits from the work mentioned above have already been further validated in follow-up studies in vivo. For example, In acio and colleagues showed that parasite infection induces an ER (endoplasmic reticulum) stress response in hepatocytes, activating proteins of the unfolded protein response pathway [43] . Exogenous pharmaceutical activation of the ER stress response in vivo prior to infection with P. berghei sporozoites yielded a higher number of liver stages, but no size change (i.e., maturation status), at 24 h after infection. Another example is heme oxygenase 1 (HO-1) which was identified as a main host factor required for rodent Plasmodium infection [44] . Interestingly, while the initial screening that identified HO-1 to be up-regulated upon infection was performed in hepatoma cell lines, immunohistochemical stainings of liver sections revealed that HO-1 is induced even more robustly in Kupffer cells (liver-resident macrophages). Congruently, mechanistic studies revealed that HO-1 plays an anti-inflammatory role protecting liver stages from the immune response of the host, and siRNA-mediated knock-down of this factor in vivo nearly abolished liver-stage infection. This example nicely illustrates that while in vitro screenings in single cell types can provide clues on which factors might be involved, it is key to dissect the parasite-host interactions in a more physiologically relevant system that encompasses all cell types, to fully understand the host's contribution(s).
Accordingly, it should be rewarding to try and identify host factors related to Plasmodium infection directly in vivo in the mouse liver. Indeed, a recent measurement of transcriptome changes in the murine liver upon Plasmodium infection has revealed a strong induction of 89 interferon-stimulated genes (ISGs) linked to the type I interferon (IFN) signaling pathway [45, 46] . It was demonstrated that the host hepatocyte senses intrahepatic parasite infection by pattern recognition of cytoplasmic Plasmodium RNA via the MDA5 (melanoma differentiation-associated gene 5)/ MAVS (mitochondrial antiviral signaling protein) pathway. This in turn leads to the transcription of IFN-a/b that finally triggers a type I IFN response in hepatocytes and leukocytes, in an autocrine and paracrine manner. Knock-out of this type I IFN response increased parasite liver infection, while an induction of type I IFN prior to Plasmodium infection led to a significant reduction in liver parasite load. While it remains unclear how parasite RNA reaches the hepatocyte cytoplasm, the study by Liehl et al. demonstrates that, in contrast to previous assumptions, the host innate immune response indeed recognizes and acts against Plasmodium liver-stage infection [45] .
Importantly, not all host responses to Plasmodium infection can be measured as changes in mRNA levels. Instead, the host cell might also respond with alterations on the translational or post-translational level, for example, by adjusting the phosphorylation status of members of different signaling cascades. This vital type of host responses would therefore be missed when only quantifying transcript levels. Consequently, one study by Kaushansky et al. addressed perturbations on the protein level after Plasmodium infection using reverse-phase protein microarray technology [47] . Although restricted to a subset of proteins by the antibody selection, the authors were able to detect a generally antiapoptotic, proliferative, and antiautophagic environment in the host cell. Specifically, the tumor suppressor, p53, was largely decreased in infected hepatocytes, while the phosphorylated form of Bcl-2, involved in antiapoptotic signaling, was elevated. A deliberate increase in p53 levels, either by overexpression or by application of the drug, nutlin-3, that inhibits p53 degradation, reduced liver-stage burden in vitro and in vivo. Of note, drug-mediated increase in p53 is currently being evaluated in several clinical trials as a potential treatment for a variety of cancers [48] . This exemplifies how the study of malaria host factors as therapeutic targets might benefit from synergisms with other research areas sharing the same focus.
Next to proteins, an additional class of important host factors are microRNA (miRNA), roughly 22-nucleotide-long RNA that are master regulators of at least 60% of all mammalian genes and as such play central roles in pathological processes, including cancer and pathogen infections [49] . Recently, we dissected the effects of Plasmodium sporozoite infection on host miRNA expression under physiologically relevant conditions in livers of adult mice [50] . Combined microarray and PCR screens using total liver RNA obtained after infection with either wild-type or attenuated Plasmodium strains revealed not only an up-regulation of IFN-associated genes (confirming and extending previous work, see above and [2, 3] ) but also a dysregulation of 11 of 698 studied miRNA. In particular, by focusing on known immunoregulatory miRNA, we found miR-155 to be highly up-regulated upon Plasmodium liver-stage infection. Moreover, we could identify Kupffer cells as the main source of this particular miRNA in the adult mouse liver. Intriguingly, miR-155 is one of the best characterized proinflammatory miRNA and plays a fundamental role in mammalian host defense mechanisms against pathogen challenge [51] . In the context of Plasmodium, we thus concluded that miR-155 boosts the immune response against liver stages. Additional evidence was that exogenous overexpression of this miRNA using hepatotropic Adenoassociated viral (AAV) gene delivery vectors improved the vaccination of mice with genetically attenuated parasites [3, 4] . In turn, this reduced the number of immunizations needed to achieve sterile protection against rechallenge with wild-type parasites from three to one [50] .
Particularly noteworthy about this study is that it illustrates two major persisting challenges in the field of malaria liver-stage research that need to be overcome and that are in the focus of the remainder of this article. (1) The first is related to the facts that (i) the infection rate of liver stages is typically very low, implying that subtle changes around the local infection site are easily overlooked among the vast majority of uninfected cells, and that (ii) there are differences between rodent and human Plasmodium strains that have to be accounted for. For example, P. berghei infection seems to be supported by the hepatocyte receptor c-Met that is activated by the hepatocyte growth factor, while this is not the case for P. falciparum infections [52, 53] . In addition, (iii) although rodent models are physiologically highly relevant, their routine use is hampered by ethical, financial, and logistical concerns that are inherently associated with animal experimentation. Consequently, there is a strong desire to implement and harness novel surrogate ex vivo models of an intact liver or of specific hepatic cell types that circumvent the use of live animals, and that can be customized for a given Plasmodium strain and/or experimental question. (2) The second challenge in the field is to concurrently devise means to deliberately, specifically, and robustly control the expression of putative host factors in live animals and/ or in these new surrogate systems, including gene overexpression or inhibition, in order to fully dissect their role in the hepatic Plasmodium stages. Above, we have already briefly mentioned AAV vectors as one possible solution for this second challenge. We further make a case for these particular tools below, by highlighting most recent progress in their successful use in livers in in vivo or in ex vivo organotypic models, including their engineering toward functionality in human hepatocytes. First, however, we discuss selected examples of promising liver replacement systems for the study of intrahepatic Plasmodium stages (Fig. 2) .
Back to the future-From whole livers to organotypic models and back to chimeric organs
At first glance, it may appear straight-forward to use established hepatic cell lines as a liver surrogate, considering the benefits of indefinite growth and limited costs that are inherent to transformed cell lines. Yet, there are numerous reasons that argue against this particular strategy, most notably the fact that the histotypic and phenotypic characteristics of cell lines as well as their gene/miRNA expression profiles differ substantially from their cellular counterparts within an intact liver. Adding to the seminal differences is that cells in culture typically grow in two dimensions (2D), whereas in the liver, hepatocytes and all the other cell types are embedded in a three-dimensional (3D) environment providing special architecture and hemodynamic properties. Using primary liver cells instead of cell lines increases the physiological relevance but does not solve the problem of an unnatural and inadequate microenvironment, comprising the lack of an extracellular matrix. Moreover, primary cells are difficult to obtain and culture in a differentiated state, particularly for longer periods. The latter, however, may be required to fully mimic processes that can take days or weeks in the intact liver, such as the establishment of an anti-Plasmodium immune response.
For all these reasons, major efforts have been undertaken and are currently intensifying to create more sophisticated, multicellular, and organotypic ex vivo liver models that are as close as possible to the natural environment, and that are ideally also compatible with medium-to high-throughput experimental strategies. Examples for such systems that have been developed and tested before include 3D sandwich cell cultures, microfluidic perfusion arrays, bioreactors, biochips, or hanging droplets, to name a few. These systems find broad utility in biomedical research, from hepatotoxicity testing of pharmaceutical compounds, to investigations into liver cell physiology and pathology. For more details on these various systems, we refer the reader to excellent previous review articles (e.g., [54] [55] [56] ). In the following, we will specifically highlight two ex vivo cell culture models that have recently been shown to support Plasmodium liver-stage infections and that, in our opinion, hold great promise for future malaria research for reasons explained below.
The first of these two systems, reported by Ng and colleagues in 2015 [57] , capitalizes on the possibility to differentiate induced pluripotent stem cells (iPSCs, [58, 59] ) into so-called iPSC-derived hepatocyte-like cells or, for short, iHLCs (for review see [60] ) ( Fig. 2A) . This was achieved using a 20-day differentiation protocol involving iPSC culturing in a monolayer on matrigel and exposure to various agents including fibroblast growth factor (FGF), hepatocyte growth factor (HGF), and oncostatin M. Remarkably, as demonstrated via immunostaining for specific markers of parasite liver stages (HSP70 and MSP-1), the iHLCs were susceptible to infection with sporozoites from four different Plasmodium species-berghei, yoelii (both rodent), falciparum, and vivax (both human). This was in line with the typical hepatocyte morphology of the iHLCs as well as their expression of prototypical hepatocyte markers such as albumin and alpha-1-antitrypsin. Moreover, they expressed SR-B1 and CD81, which are both host entry factors for Plasmodium (as well as for HCV). Further interesting was that the cells acquired Plasmodium susceptibility already at the hepatoblast stage on day 15 in the differentiation protocol, albeit liver-stage development seemed to be delayed or perturbed as compared to the more mature cells on day 20. Finally noteworthy is that additional treatment of the cells with the small molecule FPH1 advanced the maturation process and eventually rendered the cells sensitive to the antimalaria drug primaquine, exemplifying the potential of this system for future phenotypic drug screens.
As compared to established hepatocyte cell lines, the use of iHLCs provides a variety of advantages, most important of which is that they more accurately recapitulate parasite-host interactions. At least from a technical standpoint, the iHLC system is also superior to primary human cells since the iPSC-derived cells are renewable in culture. Another unique trait and benefit is that iPSCs and thus iHLCs can be derived from somatic cells from any human donor, offering the possibility to include a broad spectrum of the population in future assays with this system. This is essential as it will permit to assess the effects of different genotypes related to highly polymorphic genetic variants and diverse ethnic groups. In turn, this equips these cells with a much higher predictive value in drug screens or biological assays than primary cells derived from a single donor. On top of the natural heterogeneity, it should be possible to deliberately modulate the genome of iPSC/iHLCs, by exploiting easily accessible and customizable CRISPR gene-editing technology. Notably, the two essential CRISPR components (guide RNA and Cas9 nuclease) can be delivered by recombinant AAV vectors (see also below), which makes the combination of these powerful technologies-CRISPR, iHLCs, and AAV-very promising. Support for this enthusiasm comes from data provided by us and others (A-K. Herrmann & D. Grimm, unpublished results and [61] ) showing that iPSC/iHLCs can be transduced very efficiently with AAV vectors, depending on the capsid variant used for vector generation.
In this context, a recent study by Egan et al. [62] is worth highlighting as well, in which the authors used a forward shRNA screen to identify host factors for P. falciparum blood-stage development within the erythrocyte. As these cells are denucleated and therefore impervious to genetic modification, the shRNA were instead delivered to hematopoietic progenitor cells, which were subsequently matured into erythroblasts and then infected with the parasite. The fact that this permitted the identification of CD55 as an essential factor for parasite invasion into the erythrocyte further exemplifies the power of stem cell-based strategies and thus complements the work by Ng and colleagues [57] .
Taken together, the key features of the iHLC system -natural genetic diversity, possibility of deliberate mutation, and susceptibility to Plasmodium sporozoite infection during iPSC-to-iHLC differentiation-suggest a large potential for the study and dissection of parasite-host interactions. To even further enhance these prospects, it would be beneficial to standardize the differentiation protocol to facilitate its rapid implementation in other laboratories. Additionally, efforts should be undertaken to improve the degree of cell maturation, to ensure that the iHLCs truly mimic the host factor repertoire of primary hepatocytes and thus even more accurately recapitulate the situation in an intact liver.
Importantly, even with all these improvements in place, a limitation of the current iHLC system remains its concentration on a single cell type, that is, hepatocytes. However, the liver comprises a variety of other cell types that are most likely also involved in Plasmodium infection and establishment of liver stages, especially Kupffer cells, stellate cells, and liver sinusoidal endothelial cells (LSEC). In fact, there is evidence that prior to hepatocyte infection, the parasite traverses Kupffer cells and LSECs, and that this may be essential for subsequent liver-stage formation [63, 64] .
In this respect, a second novel system should be highlighted that has recently been reported by March and colleagues [65, 66] . This study is noteworthy as it describes a robust and multicellular ex vivo platform that recapitulates the complete liver stage of Plasmodium sporozoite infection, including progression to the schizont and merozoite stages. In more detail, the hallmark of this platform is micropatterned cocultivation (MPCC, [67] ) of cryopreserved primary human hepatocytes together with supportive stromal cells (murine embryonic fibroblasts) ( Fig. 2A) . Notably, the hepatocytes grown in this system polarize, exhibit typical drug and energy metabolism, do not proliferate, and maintain a functional phenotype for up to 6 weeks. In addition, high reproducibility is guaranteed through the use of cryopreserved human cells, which minimizes donor-to-donor interexperimental variability, and likewise through the use of cryopreserved, purified, vialed, and aseptic sporozoites (P. falciparum or vivax). Using a battery of assays, March and coworkers were able to validate the viability of these sporozoites and to prove their ability to mature into hepatic schizonts. Remarkably, the latter were also shown to release merozoites that were capable of infecting human red blood cells, which were added to the MPCC culture.
In comparison to regular cultures of primary human liver cells, an advantage of this system and a promising feature for its future use in malaria research is that it combines high reproducibility, robustness, and reliability, with the possibility to maintain and study functional cellular phenotypes over extended periods of time. Equally remarkable is the ability of this platform to support the full Plasmodium liver-stage infection, from sporozoite invasion to schizont/merozoite release. In this regard, it may even surpass the capabilities of the iHLC system highlighted above (albeit a direct comparison has not yet been performed). However, a potential drawback of the MPCC approach may be the lower amenability to stable genetic engineering for it is based on nonproliferating primary hepatocytes, rather than on expandable stem cells. In fact, the authors had to prescreen various batches of cryo-preserved cells in order to eventually identify two which mediated high-level sporozoite infection; similar variations in efficiency were also noted for three different frozen parasite batches. Together, this suggests that it may be more challenging with this particular system to cover the natural genotypic variation in the human population, and hence the predictive value may be lower than that of the iHLC approach. Moreover, to fully mimic an intact liver, the MPCC system will need to be expanded by other physiologically relevant cell types, especially Kupffer cells, which are likely required for Plasmodium liver infection [26, 63] .
In conclusion, there are numerous promising avenues in the field of ex vivo liver surrogate models for malaria research, two of which were highlighted above -use of iPSC as an unlimited cell source and multicellular coculture systems. An intriguing and rewarding next step should be to try and juxtapose the best features of the two strategies, that is, to establish robust protocols for iPSC differentiation into other relevant hepatic cell types, such as Kupffer cells, and to then combine all the different cell types in a single micropatterned culture vessel. Ideally, this will occur in a 3D format comprising an adequate extracellular matrix and fully mimicking the architecture and hemodynamics in an intact liver. In this respect, we also wish to note a recent series of encouraging reports on newly developed bioartificial 3D scaffolds (Fig. 2B  bottom) . This includes a study by Schanz et al. [68] who extracted small bowel segments from pigs, chemically removed the residual porcine cells, seeded the vascular structures with human endothelial cells, and eventually populated this vascularized scaffold with primary human hepatocytes. While not tested yet for susceptibility to Plasmodium infection, the fact that the engrafted hepatocytes were morphologically intact as well as functionally and metabolically highly active is certainly auspicious. Even more promising may be, however, to engineer decellularized liver scaffolds instead of bowel tissue as a biomimetic 3D matrix providing optimal gas and nutrient diffusion. In one example, Jiang et al. [69] used a combination of physical and chemical methods to decellularize whole extracted livers of mice, which were subsequently repopularized with mesenchymal stem cells (MSC) and attached to a perfusion culture system. Notably, the MSC efficiently and rapidly differentiated into HLC showing typical hepatocyte morphology, gene expression, and functionality that was maintained even after transplantion of the entire recellularized scaffold into recipient mice. Similarly, the Kurreck group has more recently reported successful decellularization of isolated rat liver 3D scaffolds and subsequent repopulation with HepG2 cells, a human hepatoma cell line [70] . Particularly noteworthy is that the authors were moreover able to demonstrate potent transduction of the engrafted cells with AAV vectors. This again exemplifies the great potential of these vectors for functional studies in ex vivo liver models, as already noted above in the context of the iHLC strategy and as further discussed in the next chapter. Akin to the other organotypic systems, it will now be important to include additional cell types that represent the physiological situation better, especially Kupffer cells and LSECs. To this end, it may again be beneficial to combine the best of multiple strategies, for example, to replace the HepG2 cells in the rat liver scaffold with MSC or iPSC, and to then differentiate them into various hepatic cell populations.
Last but not least, we wish to point out another related strategy, which is in vivo repopulation of livers with human hepatocytes in a living mouse (Fig. 2B  top) . Therefore, a subpopulation of the murine hepatocytes is destroyed deliberately (e.g., by overexpression of a suicide gene), triggering liver regeneration and creating a short window during which human hepatocytes can be transplanted and engrafted. The resulting 'humanized' mice support the life cycle of the human Plasmodium strains P. falciparum and P. vivax [71] [72] [73] [74] , thus complementing wild-type mice that are routinely used to propagate the rodent parasite strains. However, such human-chimeric mice are costly and laborious to generate. Moreover, one should consider that without further transplantation of, for instance, human immune cells or hematopoietic stem cells, all the other cell types in these mice remain of murine origin. Importantly, as described in more detail below, it is possible to engineer AAV vectors that readily transduce the human hepatocytes within these chimeric livers, again illustrating the potential of this particular vector for malaria research in various ex or in vivo liver models.
Fighting fire with fire-engineering of hepatotropic viruses to dissect and control Plasmodium liver stages Adeno-associated viruses are a large group of viruses that are endemic in many species including humans, and that have been studied intensely for the past five decades. One reason for their attractiveness is their unique biology, since AAVs strictly depend on coinfection with a second unrelated, so-called helper virus, typically Adenovirus or Herpes simplex virus. This is because AAV has only two open reading frames (ORFs; Fig. 3A left) whose differential expression results in eight proteins which play essential roles in viral gene expression, replication, and capsid formation, but which fail to mediate the entire AAV life cycle. To compensate for this deficiency, AAV hijacks multiple proteins and RNA (in the case of Adenovirus) from its helper virus, to foster its own transcription, translation, and particle egress [75] . Yet, even more appealing than this intriguing biology is an exclusive combination of features that makes AAV highly attractive and important as a basis for recombinant vectors for human gene therapy. First and foremost, AAV is believed to be apathogenic in humans, and hence AAV vectors are considered as the safest of all recombinant viruses currently under (pre-) clinical investigation. In fact, there has not been a single case of serious adverse events in any human patient treated with AAV vectors in over 100 clinical trials thus far [76, 77] . Secondly, the viral genome is very easy to engineer due its small size (roughly 4.7 kilobases) and due to the availability of AAV vector plasmids that can be readily customized using standard cloning techniques [78] . Thirdly, there are over 100 naturally occurring isolates of AAV which differ in cell specificity and infection efficiency, providing a vast toolkit for vector engineering [79] . To even further expand on this natural diversity, we and others implemented a variety of methods for molecular evolution of 'designer' AAV capsids that are tailored for a given application, for example, transduction of a specific cell type in the presence of neutralizing anti-AAV antibodies [80] [81] [82] .
In the following sections, we discuss why we believe that AAV vectors are ideally suited as a tool to study Plasmodium liver stages in ex or in vivo model systems, based on accumulating data from the recent literature and from our own research.
Versatility of the genome
In principle, there are at least three possibilities to identify, validate, or further dissect Plasmodium host factors and associated networks in liver cells: (a) overexpression, (b) RNAi-mediated inhibition (knockdown) on the mRNA level, and (c) nuclease-mediated suppression (knock-out) on the DNA level (Fig. 3A  right) . Importantly, all three are fully compatible with AAV vectors, as extensively demonstrated by us and others in the past. Their implementation is facilitated by the aforementioned fact that there are widely available, user-friendly, high-copy number AAV vector plasmids. They contain the only viral element which is required for vector generation in cis, namely, the inverted terminal repeats or ITRs. These are short (about 145 bp) hairpin sequences that flank the viral genes or the transgene expression cassette, respectively, and mediate its replication and encapsidation. Since the two AAV ORFs can be replaced entirely with foreign DNA, and since the capsid can package slightly oversized DNA (up to 120% of the length of the wildtype genome), an AAV vector construct can accommodate roughly 5.2 kb of DNA. Considering a typical size of promoter and polyadenylation elements in a range of 1 kb, this leaves about 4 to 4.5 kb for the cDNA of choice, which is probably sufficient for the majority of mammalian cDNA of interest (Fig. 3A[i] ).
Notably, in case the cDNA is sufficiently short (less than 2.4 kb including promoter and polyadenylation signal), there is also the option to embed it in a 'selfcomplementary' (sc)AAV vector genome. This is a variant of standard AAV vectors in which one of the ITRs is mutated by deleting the so-called 'terminal resolution site', that is, a short sequence that is normally nicked during replication of the AAV vector genome from single-stranded (ss) to double-stranded DNA. [83] . Consequently, scAAV genomes package as a molecule consisting of two inverted copies of the transgene; hence the reduction in the capacity for the foreign DNA cassette to about 50% of the wild-type genome (Fig. 3A [ii/iii]; the mutated ITR is labeled with an asterisk). Importantly, scAAV vectors express more rapidly and more robustly than conventional AAV vectors, because the latter package as ssDNA which has to be converted into a double-stranded molecule prior to transcription. It may thus take a ssAAV vector up to 2 weeks to reach the peak of transgene expression in cultured cells or in the liver, as compared to a few days for a scAAV counterpart [83, 84] . Therefore, one should carefully weigh the pros and cons of the two possible vector configurations when designing an experiment involving overexpression of a (putative) Plasmodium host factor from AAV vectors-larger capacity (ss vectors) versus more potent and faster transgene expression, at the cost of size (sc vectors). Clearly, if the latter has no limitation to begin with, we strongly recommend the use of scAAV vector genomes.
Unlike the situation with cDNA that vary in size, scAAV vectors are always the preferred option for strategies requiring knock-down or knock-out of Plasmodium host factors. This is because the expression cassettes to trigger RNAi with shRNA, or CRISPR with g(uide)RNA, respectively, are typically in a range of 100-700 bp, depending on the promoter used for small RNA expression (e.g., H1: 100 bp, or U6: 600 bp) [85] . This is far below the packaging limit of scAAV vectors and thus even permits the inclusion of a second expression cassette, for instance encoding a fluorescence marker to track the targeted cells (Fig. 3A[ii/iii] ). In fact, we have recently created a toolbox of scAAV vector templates that allow for coexpression of any shRNA or gRNA together with various fluorescence reporters, and that can be easily customized for any desired Plasmodium host factor ( [86] , and F. Schmidt, K. B€ orner & D. Grimm, unpublished results). This vector collection, which is freely available upon request, should largely foster and accelerate the future dissection of parasite-host interactions ex or in vivo.
Notably, CRISPR-based knock-out of Plasmodium host factors will also entail expression of the Cas9 nuclease, whose currently known orthologs are in a size range of 3.1-4.2 kb [87, 88] . Since all of these cDNA exceed the capacity of scAAV vectors, coexpression of Cas9 from an AAV vector requires the use of ss genomes which, as noted before, express more slowly and less efficiently than sc vectors (encoding the gRNA). Still, this is no major limitation as recently demonstrated by a variety of reports describing very efficient AAV-mediated Cas9 expression and gRNAinduced gene editing in cultured cells and livers of adult mice [86, [89] [90] [91] . In addition, the increasing availability of stable Cas9-expressing cell lines or of Cas9-transgenic mice [90] will soon entirely alleviate the need for vector-mediated Cas9 expression, at least in an exploratory context.
Efficiency in liver cells
Adeno-associated viral vectors are predestined for use in the liver or in isolated liver cells due to the fact that this organ is one of the main natural targets for the wild-type virus, in particular for the most commonly used AAV serotypes including the AAV2 prototype. This explains why vectors derived from these serotypes can readily transduce 100% of the hepatocytes in an intact mouse liver, as consistently found with, for example, AAV8 or AAV9 vectors by us and many others [84, 92, 93] . Of note, this complete liver transduction is observed after peripheral vector application via tail vein injection, which is a simple and rapid procedure that can be quickly adapted in any laboratory. One should also not get discouraged by the AAV particle numbers that have to be administered to achieve 100% transduction in vivo, and that are typically in a range of 1 9 10 11 per mouse or higher. In fact, thanks to the highly advanced AAV vector production technology, it is feasible to generate stocks with titers of greater than 1 9 10 13 particles per mL within 2 weeks, using standard cell culture techniques that are already available in the majority of laboratories [78] .
Next to the mouse, AAV vectors are also very efficient at transducing livers of larger animal species, such as dogs and nonhuman primates. While not all of these animals are already used in malaria research, it is important to realize that, in principle, the same vector constructs exploited in mice to identify or validate parasite host factors can also be translated into these larger animals. This is particularly beneficial for candidates that hold biomedical potential as malaria therapeutics or vaccines, and hence require extensive preclinical investigation in different small and large animal species. Likewise, important in this context is to again highlight the extensive clinical experience with AAV vectors in humans, which has been gathered in over 100 patient trials thus far and which is utmost encouraging. Most notable with respect to malaria research on Plasmodium liver stages are the latest clinical trials with scAAV8 vectors in patients suffering from hemophilia B, a bleeding disorder caused by defects in the human blood clotting factor IX. Following a single peripheral AAV vector administration, the majority of treated patients expressed stable factor IX levels above the critical threshold needed to provide therapeutic benefit (50 ng per mL, that is, 1% of normal) [94, 95] . None of the patients, neither in this trial nor in any other AAV-based clinical study experienced serious adverse events related to the vector, again illustrating the safety of the recombinant AAV system. It is finally also essential in this context to understand that a recent report claiming an association of AAV infection with hepatocellular carcinoma in humans attributed this effect to wild-type AAV2, but not to AAV vectors [96] . Moreover, this study has been highly criticized within the AAV community for potentially overstating the results [76, 77] , and based on the aforementioned clinical evidence that AAV vectors are exceptionally safe in human patients. Besides, further evidence for the safety and promise of AAV vectors in humans is that the first gene therapy product approved in the Western world in 2012, Glybera, is derived from a recombinant AAV serotype 1 vector [97] .
In addition to their great potential in vivo, AAV vectors are likewise highly efficient in liver cell lines or primary cells that are cultured ex vivo. This comprises numerous hepatoma cell lines, such as Huh7 or HepG2, all of which can be transduced very robustly with, for example, AAV2 or AAV6 vectors. Importantly, these cell lines retain their high susceptibility to AAV transduction even when grown in a 3D environment rather than a 2D monolayer. This has recently been exemplified in the aforementioned study by Wagner and colleagues [70] who engrafted HepG2 cells onto decellularized rat liver scaffolds and then demonstrated wide-spread and efficient transduction with an AAV6 vector. Comparable findings were made with primary mouse or human hepatocytes that can be transduced with various AAV serotypes when cultured in both, 2D or 3D structures such as spheroids [80, 98] (K. Bo¨rner & D. Grimm, unpublished results).
In view of these attractive features, it is not surprising that one can find an exhaustive list of published examples for biomedical AAV vector applications in cultured liver cells or whole livers in vivo, including in humans as mentioned above. Particularly noteworthy with respect to the topic of the current article are studies showing the successful development and use of AAV vectors expressing shRNA or shmiRNA (different types of RNAi triggers) directed against liver pathogens. For instance, we and several other groups have previously engineered scAAV vectors from hepatotropic serotypes, such as AAV7, 8, or 9, to express shRNA against Hepatitis B virus (HBV) and then proved their efficacy in cultured liver cell lines as well as in livers of HBV-transgenic mice [84, 99, 100] . Best results include the robust and persistent suppression of HBV gene expression in adult mice for over 1 year, achieved with a scAAV8 vector that was optimized for hepatocyte-specific shRNA expression from a RNA polymerase II promoter [99] . An important lesson learned in this and other in vivo studies using AAV/RNAi vectors is that vector-mediated shRNA expression needs to be tightly controlled, in order to avoid adverse oversaturation of the endogenous cellular miRNA pathway and ensuing cytotoxicity. This risk was first discovered by us in a 2006 study in which we had inadvertently triggered liver damage and animal fatalities during our evaluation of a battery of anti-HBV AAV/shRNA vectors in livers of HBV-transgenic mice [84] . As these effects are predominantly dose-dependent, we and others subsequently designed optimized AAV vectors that use weaker and/or hepatocyte-specific promoters (see above) for shRNA expression and thus alleviate the oversaturation concern. In addition, concurrent overexpression of Exportin-5 and Argonaute-2, two major rate-limiting factors in the mammalian RNAi pathway, can further improve AAV/RNAi vector safety and efficiency in cells and mouse livers [84, 101, 102] . Yet another critical parameter is the on-versus offtarget specificity of the encoded shRNA, which has to be considered for both shRNA strands, that is, the antisense strand directed against the actual target as well as the passenger strand. In fact, we have found recently that both shRNA strands are usually active, and that deliberate suppression of passenger strand activity using a 'tough decoy' inhibitor improves potency and efficiency of AAV/shRNA vectors targeting HCV or HBV [103] (T. Michler, S. Grosse, M. Heikenwalder, U. Protzer & D. Grimm, unpublished results). Altogether, these findings yield a variety of options to fine-tune the activity and in particular the safety of shRNA-expressing AAV vectors for use in animal or human liver in vivo, which provides a very solid basis for their future development in the context of malaria research. To this end, it is highly beneficial that AAV/RNAi vectors can also be evaluated and optimized in ex vivo 3D organotypic liver models, as recently exemplified by up to 90% knock-down of human cyclophilin B gene expression in a recellularized rat liver scaffold [70] .
Next to RNAi, similarly encouraging data are also already available for the combination of AAV vectors and the CRISPR gene editing system in liver cell lines or mouse livers in vivo, although CRISPR technology is much younger than RNAi. Most notable results thus far include a report of over 40% in vivo modification of the Pcsk9 gene, resulting in significant reductions in serum cholesterol [89] , as well as a recent study achieving functional correction of a mutation in the ornithine transcarbamylase gene in livers of newborn mice [104] . In both cases, appropriate gRNA were delivered with an AAV8 vector together with Cas9 from Staphylococcus aureus, the smallest of all currently known Cas9 variants (3.1 kb); the latter was either encoded in a second [104] or on the same [89] vector. Moreover, as noted above, our own groups have reported a user-friendly AAV vector toolbox for cloning and expression of custom gRNA, alone or from an 'all-in-one' vector also comprising the Cas9 cDNA [86] . Collectively, these first in vivo data and the availability of customizable gRNA templates should pave the way for the looming application of the CRISPR system as a novel, powerful, and versatile tool to further dissect Plasmodium liver stages and associated host factors.
Adaptability of the capsid
As described in the previous two paragraphs, there are a variety of naturally occurring AAV serotypes that robustly transduce cultured liver cell lines (e.g., AAV2 or AAV6) or livers of newborn or adult mice (e.g., AAV8 or AAV9). Important to point out, the hepatic cell type that is predominantly targeted by all these capsid variants are hepatocytes (or hepatocyte-derived cell lines, respectively). In contrast, other, nonparenchymal liver cell types that are relevant and interesting in the malaria liver-stage context, that is, Kupffer cells, stellate cells, and LSECs, are largely refractory to transduction with wild-type AAV capsids. In our previous work, we did observe AAV8 activity in Kupffer cells in mouse livers following systemic vector administration, but the efficiency was clearly below that in hepatocytes in the same animals [50] . We have recently made similar findings for another wild-type serotype, AAV6, and stellate cells in mouse liver (D. Grimm & H. Willenbring, unpublished results).
Fortunately, there are at least two major possibilities to improve AAV targeting to nonhepatocyte cell types in the liver (Fig 3B) . One is to alter the host environment, or, more specifically, to modify the surface composition of the cells of interest, in order to increase the binding avidity of AAV serotypes (Fig 3B  [i] ). However, a drawback of this strategy, especially when used in combination with in vivo Plasmodium infection, is that it globally alters the configuration of cells in the liver and is thus prone to creating artifacts. Nonetheless, a notable example was reported by the Asokan group who treated mice with intravenously administered recombinant sialidase, knowing that this would lead to cell surface exposure of N-terminal galactose, a receptor for AAV9. Indeed, this resulted in a marked change in the overall tropism of AAV9, including a sequestration in Kupffer cells and LSECs [105] .
Because of the practical restrictions of this approach, it is more adequate and more promising for malaria research to pursue a second strategy to retarget AAV vectors to nonparenchymal liver cells, namely, genetic modification of the viral capsid (Fig 3B[ii] ). For details on the underlying complex technology, we refer the reader to a set of excellent recent reviews [81, [106] [107] [108] . Here, suffice it to highlight what we consider as the most versatile strategy for AAV capsid diversification, that is, 'shuffling' of the capsid genes from multiple different AAV serotypes through enzymatic fragmentation and subsequent reassembly based on partial homologies. In 2008, we have introduced this technology into the AAV field and used it to molecularly evolve the capsid AAV-DJ, a unique chimera between wild-type serotypes AAV2, 8, and 9 that combines high activity in both, cultured cells including hepatoma lines and livers (hepatocytes) of adult mice [80] . In addition, more recently [109] , Lisowski and colleagues reported the capsid LK03 which had been enriched from a shuffled AAV capsid library by iterative screening in livers of human-chimeric mice. Interestingly, this capsid appears to have a higher efficiency in human hepatocytes than AAV8, which was tested in parallel as the gold standard (based on its high efficiency in mouse hepatocytes). Most likely, the elevated potency of LK03 is related to the fact over 95% of its sequence are identical to wildtype AAV3, which others also found to work well in human hepatocytes [110, 111] .
Because these data clearly illustrate the tremendous potential of DNA shuffling technology, we consider it highly rewarding to now apply the same capsid evolution and selection strategy to other cell types in the liver as well. Ideally, this will eventually result in an AAV vector toolbox permitting to specifically target any given cell population, either in an intact liver or in complex cell culture systems. This will in turn allow to overexpress or inhibit any desired putative Plasmodium host factor (provided its cDNA size is compatible with AAV, see above) and, ultimately, to thus fully unravel the intricate parasite-host interactions in all relevant liver cell types. Toward this aim, it should be useful to further juxtapose retargeting strategies based on AAV capsid modification with synergistic other approaches, such as the use of cell type-specific promoters (Fig 3B  [iii] ), or cellular detargeting through incorporation of selected miRNA-binding sites into the vector (Fig 3B  [iv] ). For instance, one candidate miRNA that could be exploited for this purpose is miR-122, as it is exclusively present in hepatocytes and can thus be harnessed to detarget AAV vectors from this cell type [86, 112, 113] .
Experience in malaria context
In light of the numerous benefits and features of AAV vectors outlined above, it should be evident why they are increasingly used in malaria research. Already, one can distinguish at least four distinct applications in the literature, and we can readily anticipate that many more will be tested soon. Firstly, several reports described the use of AAV1 vectors to express different malarial antigens-MSP4 (merozoite surface protein 4, P. falciparum) or MSP4/5 (P. yoelii)-in the muscle of mice. These antigens were either expressed alone [114] , or, in efforts to augment the immune response, as fusions with, for example, C3d 3 [115] or CTLA4-Ig [116] . Curiously, all these efforts resulted in antigenspecific immunity but failed to elicit protection against Plasmodium infection, implying that further improvements to this particular approach are required. Secondly, Huang and colleagues exemplified the usefulness of AAV9 vectors to foster reconstitution of immunodeficient mice with a human immune system [117] . Therefore, the vectors were engineered to deliver a cocktail of HLA class II genes, genes encoding various human cytokines and human B-cell activation factor. Vector administration followed by engraftment of hematopoietic stem cells resulted in humanized mice carrying human CD4+ T-and B-cells. Notably, these animals could be immunized with recombinant P. falciparum CSP and were subsequently protected from in vivo challenge with sporozoites. Also, their sera inihibited parasite invasion into HepG2 hepatoma cells in vitro, further validating the power of this mouse model to investigate human immune mechanisms of antibody-based malaria vaccines. Thirdly, Deal et al. studied a vectored immunoprophylaxis (VIP) strategy by exploiting intramuscularly injected AAV8 vectors to express antibodies against P. falciparum CSP [118] . Remarkably, up to 70% of treated mice were protected long-term from either intravenous or mosquito bite challenge with sporozoites, in an antibody dosedependent manner. This clearly shows the great potential of AAV-based VIP approaches to confer immunity to infection, albeit a number of parameters still need to be elucidated and optimized prior to clinical translation in humans, such as the effective antibody levels and the best sporozoite and/or pre-erythrocytic antigen targets.
Lastly, our own two groups have previously harnessed AAV8 vectors to dysregulate miR-155 in mouse livers prior to vaccination with genetically attenuated P. berghei parasites (GAP, [3, 4] ), following our discovery that this immunoregulatory host miRNA is highly elevated upon Plasmodium liverstage infection [50] . Our concomitant result that GAP infusion stimulates expression of TNFa (tumor necrosis factor alpha) and IFNc shed light on the underlying molecular mechanism, considering that these two cytokines are known upstream regulators of miR-155 expression. Most notable was, however, our finding that AAV8 vector-mediated miR-155 overexpression in hepatocytes and Kupffer cells boosts the protective capacity of the GAP vaccine. This exemplifies how AAV vector technology can be used not only to better dissect host-parasite interactions in the liver, but concurrently also to develop novel biomedically relevant tools and strategies.
Concluding remarks
Over the past decade, there has been tremendous and impressive progress in all research areas that were in the center of this article, culminating in an improved understanding of Plasmodium-host interactions, an arsenal of novel surrogate models of mammalian livers, and an ever expanding repertoire of technologies for AAV vector engineering. In view of the rapid pace at which these advances were made, we can readily anticipate that the continued optimization and combination of these synergistic avenues holds great potential to propel both basic and applied malaria research fast forward, and to hopefully result in the eventual eradication of this devastating disease.
